Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 368

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Open access
Saatci, Ozge, Kaymak, Aysegul, Raza, Umar, Ersan, Pelin G., Akbulut, Ozge, Banister, Carolyn E., Sikirzhytski, Vitali, Tokat, Unal Metin, Aykut, Gamze, Ansari, Suhail A., Dogan, Hayriye Tatli, Dogan, Mehmet, Jandaghi, Pouria, Isik, Aynur, Gundogdu, Fatma, Kosemehmetoglu, Kemal, Dizdar, Omer, Aksoy, Sercan, Akyol, Aytekin, Uner, Aysegul, Buckhaults, Phillip J., Riazalhosseini, Yasser, Sahin, Ozgur·2020·Nature Communications

Abstract

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RNA-sequencing. Inhibiting LOX reduces collagen cross-linking and fibronectin assembly, increases drug penetration, and downregulates ITGA5/FN1 expression, resulting in inhibition of FAK/Src signaling, induction of apoptosis and re-sensitization to chemotherapy. Similarly, inhibiting FAK/Src results in chemosensitization. These effects are observed in 3D-cultured cell lines, tumor organoids, chemoresistant xenografts, syngeneic tumors and PDX models. Re-expressing the hypoxia-repressed miR-142-3p, which targets HIF1A, LOX and ITGA5, causes further suppression of the HIF-1α/LOX/ITGA5/FN1 axis. Notably, higher LOX, ITGA5, or FN1, or lower miR-142-3p levels are associated with shorter survival in chemotherapy-treated TNBC patients. These results provide strong pre-clinical rationale for developing and testing LOX inhibitors to overcome chemoresistance in TNBC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-16199-4

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 68 references

Cited by

See all 368

Metadata

Authors
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., Dogan, H. T., Dogan, M., Jandaghi, P., Isik, A., Gundogdu, F., Kosemehmetoglu, K., Dizdar, O., Aksoy, S., Akyol, A., Uner, A., Buckhaults, P. J., Riazalhosseini, Y., & Sahin, O.
Venue
Nature Communications
Published
2020-05-15
Volume
11
Issue
1
Pages
2416-2416
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3024966196
Cited by
368
References
68
FWCI
13.37
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. https://app.cochat.ai/papers/10.1038/s41467-020-16199-4
The paper
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., Dogan, H. T., Dogan, M., Jandaghi, P., Isik, A., Gundogdu, F., Kosemehmetoglu, K., Dizdar, O., Aksoy, S., Akyol, A., . . . Sahin, O. (2020). Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications. https://doi.org/10.1038/s41467-020-16199-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.